|
|
|
|
|
|
by gus_massa
3928 days ago
|
|
|
From the article: > A fosfoetanolamina, atualmente, possui dados experimentais concluídas de fase I, II e III. The problem with the press coverage is that it has too few information. In this case it sounds too good to be true. Usually the drug is useful against some kind of cancers, but not against others. (For example, useful against fast growing cancers, but not useful against slow growing cancers.) I want a link to the a fase III study to see the relevant information. Most press coverage have a few success stories, for example someone that had a 20% reduction of the cancer in the last months. (Usually it's a measurement problem, they take two images with slightly different methods, and the second image look smaller.) It's extremely suspicious that this article doesn't even have one of this anecdotes. |
|
|